Georgina Long, Translational Research and Medical Oncology at the University of Sydney, shared a post on X:
“So proud to see my mentee Assoc Professor Ines da Silva chairing ‘Management of High-Risk Stage II Melanoma and Beyond: A Case-Based Multidisciplinary Discussion’ at ASCO26 in Chicago.
The best part of this work is seeing the people you believe in step fully into their own. The 4th photo is the MIA crew together at ASCO after the ‘Rapid Melanoma Orals’ – nine studies in melanoma and skin cancer.
Three studies that caught my eye: Anti-PD1 working in basal cell carcinoma of the head and neck – often difficult to resect, so this matters. Intralesional daromun (L19IL2/L19TNF) – relapse-free survival benefit holding up beyond 3 yrs.
Watching this one closely. Time of day for immunotherapy infusion? Another retrospective study, but this time, no difference. Science moving. Patients benefiting. Watch this space for Melanoma Orals on Monday and Melanoma Posters on Sunday.
Drug development and curing cancer is my passion.”
Other articles featuring Georgina Long on OncoDaily.
